SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-030746
Filing Date
2019-08-08
Accepted
2019-08-08 16:01:39
Documents
68
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q spro-10q_20190630.htm 10-Q 3133173
2 EX-10.1 spro-ex101_229.htm EX-10.1 141474
3 EX-31.1 spro-ex311_8.htm EX-31.1 22172
4 EX-31.2 spro-ex312_7.htm EX-31.2 22403
5 EX-32.1 spro-ex321_9.htm EX-32.1 9816
6 EX-32.2 spro-ex322_6.htm EX-32.2 9833
  Complete submission text file 0001564590-19-030746.txt   9659321

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT spro-20190630.xml EX-101.INS 2007453
8 XBRL TAXONOMY EXTENSION SCHEMA spro-20190630.xsd EX-101.SCH 68585
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE spro-20190630_cal.xml EX-101.CAL 56252
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE spro-20190630_def.xml EX-101.DEF 212611
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20190630_lab.xml EX-101.LAB 481816
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20190630_pre.xml EX-101.PRE 366834
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 191009399
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences